gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Six transmembrane epithelial antigen of the prostate 1

STEAP, STEAP1, Six-transmembrane epithelial antigen of the prostate
This gene is predominantly expressed in prostate tissue, and is found to be upregulated in multiple cancer cell lines. The gene product is predicted to be a six-transmembrane protein, and was shown to be a cell surface antigen significantly expressed at cell-cell junctions. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CAN, TIARP, ACID, STEAP2, Steap3
Papers on STEAP
Characterization of a single b-type heme, FAD, and metal binding sites in the transmembrane domain of six-transmembrane epithelial antigen of the prostate (STEAP) family proteins.
New
Lawrence et al., Bozeman, United States. In J Biol Chem, Oct 2015
Six-transmembrane epithelial antigen of the prostate 3 (Steap3) is the major ferric reductase in developing erythrocytes.
Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates.
New
Lin et al., San Francisco, United States. In Pharm Res, Jun 2015
METHOD: Pharmacokinetics studies were conducted for unconjugated antibody and purified TDCs with DAR-1, 2 and 4 for trastuzumab TDC and Anti-STEAP1 TDC in mice.
Identification of novel vascular targets in lung cancer.
New
Bicknell et al., Birmingham, United Kingdom. In Br J Cancer, Mar 2015
Further detailed expression profiling of STEAP1 on 82 lung cancer patients confirmed STEAP1 as a novel target in the tumour vasculature.
Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.
Lewis et al., New York City, United States. In J Nucl Med, 2014
UNLABELLED: Antibodies and antibody-drug conjugates targeting the cell surface protein 6 transmembrane epithelial antigen of prostate 1 (STEAP1) are in early clinical development for the treatment of castration-resistant prostate cancer (PCa).
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.
Stenzl et al., München, Germany. In J Immunother Cancer, 2014
BACKGROUND: CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA (RNActive®) encoding the antigens PSA, PSCA, PSMA, and STEAP1.
A role for STEAP2 in prostate cancer progression.
Doak et al., Swansea, United Kingdom. In Clin Exp Metastasis, 2014
Of particular interest was six transmembrane epithelial antigen of the prostate (STEAP) 1 and STEAP 2 which was subsequently analysed further in prostate cancer tissue samples following optimisation of an RNA extraction method from laser captured cells isolated from formalin-fixed paraffin-embedded biopsy samples.
Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.
Rossig et al., Münster, Germany. In Cancer Immunol Immunother, 2014
Candidate antigens in EwS include six-transmembrane epithelial antigen of the prostate-1 (STEAP1), and the human cancer/testis antigens X-antigen family member 1 (XAGE1) and preferentially expressed antigen in melanoma (PRAME).
Expression of STEAP1 and STEAP1B in prostate cell lines, and the putative regulation of STEAP1 by post-transcriptional and post-translational mechanisms.
Maia et al., Covilhã, Portugal. In Genes Cancer, 2014
STEAP1 gene is overexpressed in several kinds of tumors, particularly in prostate cancer.
STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Maia et al., Covilhã, Portugal. In Urol Oncol, 2014
BACKGROUND: Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a transmembrane protein of epithelial cells, mostly located at cell-cell junctions, and is overexpressed in several types of tumors, particularly prostate cancer.
The role of inflammation in bladder cancer.
Review
Gakis, Tübingen, Germany. In Adv Exp Med Biol, 2013
T cells are capable of increasing the oxidative stress on bladder cancer cells via induction of COX-2 and STEAP expression.
CBX7 modulates the expression of genes critical for cancer progression.
Fusco et al., Napoli, Italy. In Plos One, 2013
RESULTS: We found that CBX7 negatively or positively regulates the expression of several genes (such as SPP1, SPINK1, STEAP1, and FOS, FOSB, EGR1, respectively) associated to cancer progression, by interacting with their promoter regions and modulating their transcriptional activity.
STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma.
Rogatto et al., Botucatu, Brazil. In Histopathology, 2013
AIMS: To investigate the prognostic value of expression levels of the genes STEAP1 and STEAP2, and of STEAP1 protein, in prostate carcinomas (PCa).
Six-transmembrane epithelial antigen of the prostate-1 plays a role for in vivo tumor growth via intercellular communication.
Sato et al., Sapporo, Japan. In Exp Cell Res, 2013
Six-transmembrane epithelial antigen of the prostate-1 (STEAP-1) is a novel cell surface protein overexpressed only in the prostate among normal tissues and various types of cancer including prostate, bladder, lung, and ovarian cancer.
High STEAP1 expression is associated with improved outcome of Ewing's sarcoma patients.
GeneRIF
Burdach et al., München, Germany. In Ann Oncol, 2012
STEAP1 overexpression predicts improved outcome of Ewing's sarcoma patients, possibly due to enhanced sensitivity towards ROS-generating chemotherapeutics.
STEAP proteins: from structure to applications in cancer therapy.
Review
Santos et al., Covilhã, Portugal. In Mol Cancer Res, 2012
The human 6-transmembrane epithelial antigen of prostate (STEAP) family comprises STEAP1, STEAP2, STEAP3, and STEAP4.
Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
GeneRIF
Rossig et al., Münster, Germany. In Cancer Immunol Immunother, 2012
Studies suggest that activated human gammadelta T cells can efficiently present PRAME and STEAP1-derived epitopes and allow breaking tolerance against these tumor-associated self-antigens.
STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors.
GeneRIF
Burdach et al., Germany. In Mol Cancer Res, 2012
STEAP1 is associated with the invasive behavior and oxidative stress phenotype of Ewing tumors, an unanticipated oncogenic function of STEAP1.
Ironing out cancer.
Review
Torti et al., Winston-Salem, United States. In Cancer Res, 2011
Discoveries of the roles of ferroportin, hepcidin, lipocalin 2, and members of the six transmembrane epithelial antigen of the prostate (STEAP) and iron regulatory protein (IRP) families in cancer have provided specificity and molecular definition to the role of iron homeostasis in cancer growth and metastasis.
Zoledronic acid decreases mRNA six-transmembrane epithelial antigen of prostate protein expression in prostate cancer cells.
GeneRIF
Dalle Carbonare et al., Verona, Italy. In J Endocrinol Invest, 2010
Data suggest that zoledronic acid may affect cancer cells also by targeting the gene expression of STEAP.
Six-transmembrane epithelial antigen of the prostate (STEAP1 and STEAP2)-differentially expressed by murine and human mesenchymal stem cells.
GeneRIF
Murphy et al., London, United Kingdom. In Tissue Eng Part A, 2009
STEAPs may represent novel markers of mesenchymal stem cells in man as well as mice.
share on facebooktweetadd +1mail to friends